 | |
| Clinical data | |
|---|---|
| Other names | Dibutyryl cyclic adenosine monophosphate (N6,2'-O-dibutyryl)-adenosine-3',5'-mono-phosphate Dibutyryl cAMP DcAMP DBcAMP |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.006.046 |
| Chemical and physical data | |
| Formula | C18H23N5NaO8P |
| Molar mass | 491.373 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Bucladesine is a cyclic nucleotide derivative which mimics the action of endogenouscAMP and is aphosphodiesterase inhibitor.
Bucladesine is a cell permeable cAMP analog. The compound is used in a wide variety of research applications because it mimics cAMP and can induce normal physiological responses when added to cells in experimental conditions. cAMP is only able to elicit minimal responses in these situations.
Theneurite outgrowth instigated by bucladesine in cell cultures has been shown to be enhanced bynardosinone.
The effect of bucladesine as a cAMP analog has been studied on the pentylenetetrazol-induced seizure in the wild-type mice. The data showed that bucladesine (300nM/mouse) reduced the seizure latency and threshold. In addition they found that combination of bucladesine and pentoxyfillin has additive effect on seizure latency and threshold.[1]
Bucladesine (50-100nM/mouse) showed significant attenuation in the morphine withdrawal syndrome in the wild-type mice. In addition, its high dose (200nM/mouse) combination withH-89, as a protein kinase inhibitor, had additive attenuating effect on withdrawal syndromes.[2]
 | Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |
